Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Charles River Labs 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Charles River Labs 3Q

Revenues up 5% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Labs 3Q

3Q Revenues: $292.1 million (+5%)

3Q Earnings: $31.2 million (+41%)

YTD Revenues: $876.3 million (+3%)

YTD Earnings: $84.7 million (+7%)

Comments: Research Models and Services (RMS) segment sales were $173.4 million in the quarter, up 4%, driven primarily by the acquisitions of Vital River and Accugenix, as well as growth in the legacy Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $118.7 million, up 6%, driven by increased sales to both large biopharma and mid-tier clients.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters